Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

62.79
-0.1200-0.19%
Pre-market: 62.78-0.0100-0.02%09:28 EDT
Volume:1.25M
Turnover:78.86M
Market Cap:8.73B
PE:-8.74
High:63.50
Open:62.48
Low:62.13
Close:62.91
52wk High:88.31
52wk Low:54.30
Shares:139.02M
Float Shares:138.02M
Volume Ratio:0.50
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-50.32
PE(LYR):-9.60

Loading ...

Cytokinetics announces additional data from ACACIA-HCM trial at HFSA

TIPRANKS
·
17 hours ago

Cytokinetics Says Phase 3 Acacia-HCM Data Show Aficamten Boosts Exercise Performance in Non-Obstructive HCM

Reuters
·
17 hours ago

Cytokinetics Announces Additional Data from Acacia-HCM Presented at the Hfsa Annual Scientific Meeting 2026

THOMSON REUTERS
·
17 hours ago

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

GlobeNewswire
·
17 hours ago

Cytokinetics is Maintained at Outperform by RBC Capital

Dow Jones
·
Oct 08

RBC Lifts Price Target on Cytokinetics to $113 From $112, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

Cytokinetics, Incorporated : RBC Raises Target Price to $113 from $112

THOMSON REUTERS
·
Oct 08

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of 3,500 Common Shares Valued at $214,830

Reuters
·
Oct 07

H.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Oct 05

Bumble, PIMCO Dynamic, Cytokinetics, Medifast, Grace

TIPRANKS
·
Oct 03

Cytokinetics to Present Four Aficamten Studies at HFSA Annual Scientific Meeting 2026

Reuters
·
Oct 02

Cytokinetics Announces Four Upcoming Presentations at the Hfsa Annual Scientific Meeting 2026

THOMSON REUTERS
·
Oct 02

H.C. Wainwright Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Sep 30

Cytokinetics Starts Real-World Study of Myqorzo in Obstructive Hypertrophic Cardiomyopathy

MT Newswires Live
·
Sep 30

Cytokinetics Launches Aspen-HCM: a Real-World Study Evaluating Myqorzo® (Aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Sep 30

Top Executive Makes a Bold Move With Recent Cytokinetics Stock Sale

TIPRANKS
·
Sep 29

Cytokinetics CEO Robert I. Blum Disposes of USD 490,950 in Common Shares

Reuters
·
Sep 29

Aspen Aerogels, Sezzle, PIMCO, Kimbell, Cytokinetics Insider Moves

TIPRANKS
·
Sep 26

Top Cytokinetics Executive Makes Notable Stock Move in High-Value Sale

TIPRANKS
·
Sep 23

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of Common Shares Worth $239,015

Reuters
·
Sep 23